Cardiology

Michael Felker, MD, talks about the results of the GUIDE-IT trial and the use of natriuretic peptide-guided therapy for patients with HFrEF.

Lisa Rathman, MSN, of Lancaster General Hospital, discusses the benefits of subcutaneous furosemide in nursing homes and facilities outside the hospital.

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

The ongoing phase 3 trial has been selected for accelerated approval pathways in the US and Europe.

Gregg Fonarow, MD, of UCLA, discusses the vital importance of preventing HF in ways outside of just the available treatment options.

Mandeep Mehra, MD, President of the HFSA, discusses one of the HFSA annual meeting's themes: the prophylaxis of heart failure through behavioral and dietary adjustments.

Rob Mentz, MD; David Aguilar, MD; Mandeep Mehra, MD; and Lisa Rathman, MSN, discussed the use of team-based care in heart failure, a condition plagued by comorbidities and often treated by multiple specialists.

David Aguilar, MD, of Baylor College of Medicine, discusses the new responsibilities faced by cardiologists with the emerging onset of dual-indication medicines.

Gregg Fonarow, MD, of UCLA, spoke about the benefits of short-term treatment for keeping HF patients out of hospital, and using hospitalization as a time to learn.

Mandeep Mehra, MD, President of the HFSA, discusses the importance of team-based care between physicians, pharmacists, and nurse practitioners in treating heart failure.

Bertram Pitt, MD, of the University of Michigan School of Medicine, discusses the benefits of subcutaneous furosemide keeping patients from "bouncing back" into the hospital.

Amil Shah, MD, of Harvard Medical School, discusses the utilization of echocardiography - often the first step for the indication of heart failure with preserved ejection fraction - to diagnose patients with the condition and separate them from other morbidities.

James Udelson, MD, the chief of cardiology at Tufts Medical Center, discusses the possibilities offered by the development of subcutaneous furosemide for HF patients in need of diuresis.

One study has shown that 90-day prescriptions can increase adherence over 30-day prescriptions.

Five-year mortality rates decreased 7% for those who were part of the triple-screened group of the study.

No strokes were experienced by the apixaban group, compared to 6 in the warfarin arm of the study.

A 51-year-old man is seen in ED for progressive dyspnea, near syncope on exertion, bilateral edema. What does the tracing tell you?

Rivaroxaban plus aspirin showed a 31% reduction in major cardiovascular events for PAD patients.

A new meta-analysis finds that routine intake of artificial sweeteners is linked to the opposite of the intended effect.

Despite receiving cardiac catheterization at lower rates than other weight categories, underweight patients were more likely to die, be readmitted, and have higher hospital costs.

The novel therapy showed sinus rhythm was present in 75% of patients after 1-year follow-up.

There are currently no known reports of patient harm for the 465,000 implanted devices in question, according to the FDA.

The drug was found to be most effective in its 150 mg and 300 mg doses, reducing cardiovascular events by 15% and 14%, respectively.

Catheter ablation lowered mortality rates to 13.4% and hospitalization rates to 20.7%, significant decreases compared to the conventional methods.

The drug showed a 29% reduction in risk for patients who had a myocardial infarction.

The drug will be reviewed based on the results of the phase 3 HAVEN 1 and 2 studies.

Evolocumab was shown to lower cardiovascular risk between 15 to 20% in a randomized, double-blind, placebo-controlled study.

The hospital topped the list for the second straight year.

The FDA decision regarding Zelboraf’s approval for Erdheim-Chester disease with BRAF V6000 Mutations is expected by December 2017.